Weight loss doctor Bazgha Khalid goes through what the published trials actually show for Zepbound against Lilly's newer retatrutide.
Recap by typeshit. Full story at Bazgha Khalid, MD.
6:25
Dr Almerie compares Lilly's experimental retatrutide with Mounjaro and talks through the case for switching versus holding off until it's approved.
He points to GLP-1 receptors in the hypothalamus, saying the medication boosts fullness signals and slows the stomach, which changes how hunger feels.
Patients who took a GLP-1 receptor agonist before surgery did not lose more weight at one year, JAMA Surgery reports. The full study has the details.
A clinical piece for foot and limb care providers on how GLP-1 drugs relate to the lower extremity. Only the title is available.
Dr. Shah walks through how GLP-1s work, who stands to benefit, common side effects, and NorthShore's weight management clinic.
22:55
Dr. Aleksandra Brown breaks down the buzz around copper peptides and how topical serums compare with injected GHK-Cu.
Loading…